Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
Braftovi outdoes Tafinlar in colorectal cancer
US approval gives Pfizer the first and second-line settings.
ASH 2024 – Miltenyi throws its hat into the fast-Car ring
And the company might one day follow Galapagos into decentralised manufacturing.
Janux impresses again
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
ASH 2024 preview – best of the rest
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
ASH 2024 preview – CD19 back on the agenda
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
FDA red and green lights: October 2024
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
